SCHEMBL4414040

SCHEMBL4414040

O=C(C=Cc1cc(OCc2ccccc2)c(OCc2ccccc2)c(OCc2ccccc2)c1)c1c(O)cc(OCc2ccccc2)cc1OCc1ccccc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC5A1 P13866 2/20 0.63
SLC5A2 P31639 2/20 0.63
PDE4A P27815 1/20 0.54
PDE4B Q07343 1/20 0.54
PDE4C Q08493 1/20 0.54
PDE4D Q08499 1/20 0.54
MAPT P10636 3/20 0.53
KMT2A Q03164 3/20 0.53
CYP3A4 P08684 2/20 0.53
TP53 P04637 1/20 0.53
ATM Q13315 1/20 0.53
HSD17B10 Q99714 1/20 0.53
APP P05067 2/20 0.52
ABCG2 Q9UNQ0 3/20 0.50
MEN1 O00255 2/20 0.48
KCNA3 P22001 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
CYP19A1 P11511 1/20 0.48
CYP2C9 P11712 1/20 0.48
MAOA P21397 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13117246 1.00 SLC5A1 (0.63) SLC5A1SLC5A2PDE4APDE4BPDE4C
SCHEMBL29179321 0.95 PDE4A (0.63) SLC5A1SLC5A2PDE4APDE4BPDE4C
SCHEMBL30892448 0.95 PDE4A (0.63) SLC5A1SLC5A2PDE4APDE4BPDE4C
SCHEMBL24983864 0.95 PDE4A (0.63) SLC5A1SLC5A2PDE4APDE4BPDE4C
SCHEMBL30141094 0.95 PDE4A (0.63) SLC5A1SLC5A2PDE4APDE4BPDE4C
SCHEMBL1727986 0.91 SLC5A1 (0.72) SLC5A1SLC5A2PDE4APDE4BPDE4C
SCHEMBL1727983 0.91 SLC5A1 (0.72) SLC5A1SLC5A2PDE4APDE4BPDE4C
SCHEMBL30383800 0.91 SLC5A1 (0.72) SLC5A1SLC5A2PDE4APDE4BPDE4C
SCHEMBL5838566 0.89 MAPT (0.70) SLC5A1SLC5A2PDE4APDE4BPDE4C
SCHEMBL5838556 0.89 MAPT (0.70) SLC5A1SLC5A2PDE4APDE4BPDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7638554-B2 Flavanoids as chemotherapeutic, chemopreventive, and antiangiogenic agents SRI INTERNATIONAL (US) 2009-12-29 US disclosed
US-7329687-B2 Flavanoid compounds as chemotherapeutic, chemopreventive, and antiangiogenic agents SRI INTERNATIONAL (US) 2008-02-12 US disclosed
US-20060264500-A1 Novel flavanoids as chemotherapeutic, chemopreventive, and antiangiogenic agents SRI INTERNATIONAL (US) 2006-11-23 US disclosed
EP-1495014-A2 NOVEL FLAVANOIDS AND CHALCONES AS CHEMOTHERAPEUTIC, CHEMOPREVENTIVE, AND ANTIANGIOGENIC AGENTS Sri International (US) 2005-01-12 EP disclosed
US-20040029914-A1 Novel flavanoids as chemotherapeutic, chemopreventive, and antiangiogenic agents SRI INTERNATIONAL 2004-02-12 US disclosed
US-20030229136-A1 Novel flavanoids as chemotherapeutic, chemopreventive, and antiangiogenic agents SRI INTERNATIONAL 2003-12-11 US disclosed
WO-2003089423-A2 NOVEL FLAVANOIDS AND CHALCONES AS CHEMOTHERAPEUTIC, CHEMOPREVENTIVE, AND ANTIANGIOGENIC AGENTS SRI INTERNATIONAL (US) 2003-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060264500-A1 Novel flavanoids as chemotherapeutic, chemopreventive, and antiangiogenic agents FLT1, CCNE1, CCNA1 SLC5A1 1841/4885SLC5A2 3536/4885PDE4A 2763/4885
US-20040029914-A1 Novel flavanoids as chemotherapeutic, chemopreventive, and antiangiogenic agents FLT1, VEGFA, FLT4 SLC5A1 1010/4885SLC5A2 2623/4885PDE4A 3123/4885
US-20030229136-A1 Novel flavanoids as chemotherapeutic, chemopreventive, and antiangiogenic agents FLT1, VEGFA, FLT4 SLC5A1 1118/4885SLC5A2 2651/4885PDE4A 3215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.